Clinical Trial

Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resistant Schizophrenia

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Previous study found that some NMDA-enhancing agent was able to augment efficacy of clozapine for clinical symptoms but not cognitive function in the treatment of ultra-resistant schizophrenia. In addition, several drugs with anti-inflammatory properties have been tested in clinical trials for the treatment of schizophrenia. Whether a drug with anti-inflammatory property can strengthen the efficacy of an NMDA-enhancer (NMDAE) in the treatment of ultra-resistant schizophrenia remains unknown.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-02-06; most recent amendment 2026-03-21.
Status change: Not Yet Recruiting → Recruiting 2022-02-23
Trial Details
NCT Number NCT05240976
Lead Sponsor China Medical University Hospital
Collaborators: National Health Research Institutes, Taiwan
Conditions Schizophrenia
Enrollment 80 participants
Start Date 2022-02-23
Primary Completion 2027-02 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-03-24